Actively Recruiting

Phase Not Applicable
Age: 18Years +
All Genders
NCT06936618

EIT-Guided Ventilator Settings in AHRF

Led by Mahidol University · Updated on 2025-04-27

17

Participants Needed

1

Research Sites

102 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

This exploratory study aims to investigate the effect of Electrical Impedance Tomography (EIT)-guided ventilator settings on mechanical power in patients with acute hypoxemic respiratory failure (AHRF), including both ARDS and non-ARDS conditions. Mechanical power, a key factor associated with ventilator-induced lung injury (VILI), will be measured before and after EIT-guided PEEP titration. The study will evaluate feasibility and changes in lung mechanics, gas exchange, and EIT parameters. A total of 17 patients requiring invasive mechanical ventilation will be enrolled at Siriraj Hospital, Mahidol University.

CONDITIONS

Official Title

EIT-Guided Ventilator Settings in AHRF

Who Can Participate

Age: 18Years +
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Age ≥ 18 years
  • Diagnosed with acute hypoxemic respiratory failure within 48 hours
  • Expected to require invasive mechanical ventilation ≥ 48 hours
  • On mechanical ventilation within 24 hours
  • Deep sedation and neuromuscular blockade
Not Eligible

You will not qualify if you...

  • Pregnancy
  • Body mass index (BMI) > 40 kg/m2
  • Contraindications to using electrical impedance tomography, including
  • Presence of a pacemaker or automatic implantable cardioverter-defibrillator (AICD)
  • Inability to place the belt due to presence of surgical wounds dressing, thoracic or spinal cord trauma, recent thoracic surgery, etc.
  • High risk for PEEP titration
  • Hemodynamic instability defined as mean arterial pressure < 65 mmHg despite optimization of fluid status and/or use of vasopressors
  • Unstable cardiac arrhythmias
  • Presence of lung bullae greater than 2 cm in diameter, identified on chest X-ray
  • Presence of pneumothorax or pneumomediastinum
  • Right-sided heart failure or severe pulmonary hypertension
  • Neurologic conditions associated with a risk of intracranial hypertension
  • Use of extracorporeal membrane oxygenation (ECMO)
  • Severe chronic respiratory disease, defined as follows: requiring home oxygen therapy, or previous lung function showing (FEV1 less than 20 ml/kg PBW, or FEV1/FVC less than 50% predicted value), or chronic hypercapnia (PaCO2 greater than 45 mmHg) and/or chronic hypoxemia (PaO2 less than 55 mmHg) on FIO2 = 0.21, or radiographic x-ray evidence of any chronic over-inflation or chronic interstitial infiltration, or chronic restrictive, obstructive, neuromuscular, chest wall or pulmonary vascular disease resulting in severe exercise restriction (unable to climb stairs or perform household duties, secondary polycythemia, severe pulmonary hypertension with mean pulmonary arterial pressure greater than 40 mmHg)
  • Decision to withhold life-sustaining treatment or palliative care.
  • Moribund status with an expected survival of less than 24 hours.
  • Refusal to provide informed consent

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 1 location

1

Siriraj Hospital, Mahidol University

Bangkok, Thailand, 10700

Actively Recruiting

Loading map...

Research Team

J

Jitanong Sootlek, MD, PCCM

CONTACT

R

Ranistha Ratanarat, MD, Nephrology, Critical care

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

NONE

Allocation

NA

Model

SINGLE_GROUP

Primary Purpose

TREATMENT

Number of Arms

1

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here